{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:49:27Z","timestamp":1791607767314,"version":"4.3.4"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7882-26","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:11:50Z","timestamp":1791411110000},"source":"Crossref","is-referenced-by-count":0,"title":["Hospitalized Infection Risk and Organ-specific Infection Patterns Across Advanced Therapies in Ulcerative Colitis: A Japanese Claims Analysis"],"prefix":"10.2169","author":[{"given":"Yu","family":"Nishida","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ominami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nadatani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusei","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186: 4234-4243, 2011.","DOI":"10.4049\/jimmunol.1003668"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ananthakrishnan AN, Murad MH, Scott FI, et al. Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association evidence synthesis. Gastroenterology 167: 1460-1482, 2024.","DOI":"10.1053\/j.gastro.2024.07.046"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Baumgart DC, Le Berre C. Newer biologic and small-molecule therapies for inflammatory bowel disease. N Engl J Med 385: 1302-1315, 2021.","DOI":"10.1056\/NEJMra1907607"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nishida Y, Hosomi S, Fujimoto K, et al. Lack of efficacy of concomitant 5-aminosalicylic acid with vedolizumab in inflammatory bowel disease: a large-scale administrative database analysis. Inflamm Bowel Dis 31: 2036-2039, 2025.","DOI":"10.1093\/ibd\/izaf088"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nishida Y, Hosomi S, Fujimoto K, et al. Impact of 5-aminosalicylic acid on ustekinumab in inflammatory bowel disease: a retrospective medical claims analysis. Inflamm Bowel Dis 2025.","DOI":"10.1093\/ibd\/izaf001"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nishida Y, Hosomi S, Fujimoto K, et al. Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis. J Gastroenterol Hepatol 2024.","DOI":"10.1111\/jgh.16786"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Nishida Y, Hosomi S, Fujimoto K, et al. Does 5-aminosalicylic acid prevent colorectal cancer in tumour necrosis factor: treated ulcerative colitis? a real-world study. Digestion 2025.","DOI":"10.1159\/000547093"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nishida Y, Hosomi S, Fujimoto K, et al. Thromboembolic risk in ulcerative colitis patients on advanced therapy: a real-world data analysis. Inflamm Bowel Dis 2025.","DOI":"10.1093\/ibd\/izaf302"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Sandborn WJ, Pan\u00e9s J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther 50: 1068-1076, 2019.","DOI":"10.1111\/apt.15514"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Charles-Schoeman C, Fleischmann R, Mysler E, et al. Risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors in cardiovascular risk-enriched rheumatoid arthritis patients. Arthritis Rheumatol 76: 1218-1229, 2024.","DOI":"10.1002\/art.42846"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155: 337-346.e10, 2018.","DOI":"10.1053\/j.gastro.2018.04.012"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ahuja D, Dziegielewski C, Yeh KH, et al. Comparative safety of advanced therapies in patients with ulcerative colitis: an administrative claims-based study. Am J Gastroenterol 2025.","DOI":"10.14309\/ajg.0000000000003806"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Solitano V, Facciorusso A, Jess T, et al. Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 21: 907-921.e2, 2023.","DOI":"10.1016\/j.cgh.2022.07.032"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ahuja D, Yeh KH, Patel SB, et al. Comparative safety of Janus kinase inhibitors vs tumor necrosis factor antagonists in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2025.","DOI":"10.1016\/j.cgh.2025.06.041"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Solitano V, Ahuja D, Lee HH, et al. Comparative safety of JAK inhibitors vs TNF antagonists in immune-mediated inflammatory diseases: a systematic review and meta-analysis. JAMA Netw Open 8: e2531204, 2025.","DOI":"10.1001\/jamanetworkopen.2025.31204"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Singh S, Heien HC, Herrin J, et al. Comparative risk of serious infections with tumor necrosis factor \u03b1 antagonists vs vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 20: e74-e88, 2022.","DOI":"10.1016\/j.cgh.2021.02.032"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kirchgesner J, Desai RJ, Beaugerie L, et al. Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 20: 314-324.e16, 2022.","DOI":"10.1016\/j.cgh.2020.12.030"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bertrand A, Amiot A, Martin A, et al. Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, Janus kinase inhibitors, anti-tumor necrosis factor or aminosalicylates. Clin Gastroenterol Hepatol 2026.","DOI":"10.1016\/j.cgh.2026.04.015"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Singh S, Iversen AT, Allin KH, et al. Comparative outcomes and safety of vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases. JAMA Netw Open 5: e2234200, 2022.","DOI":"10.1001\/jamanetworkopen.2022.34200"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 369: 699-710, 2013.","DOI":"10.1056\/NEJMoa1215734"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut 66: 839-851, 2017.","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Karlqvist S, Sachs MC, Eriksson C, et al. Comparative risk of serious infection with vedolizumab vs anti-tumor necrosis factor in inflammatory bowel disease: results from nationwide Swedish registers. Am J Gastroenterol 119: 2480-2492, 2024.","DOI":"10.14309\/ajg.0000000000002961"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 381: 1215-1226, 2019.","DOI":"10.1056\/NEJMoa1905725"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cheng D, Kochar BD, Cai T, et al. Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor \u03b1 antagonists in inflammatory bowel diseases. Clin Gastroenterol Hepatol 20: 2366-2372.e6, 2022.","DOI":"10.1016\/j.cgh.2022.01.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Khan N, Sundararajan R, Patel D, et al. Comparative risk of serious infections associated with treatment of inflammatory bowel disease. Inflamm Bowel Dis 2025.","DOI":"10.1093\/ibd\/izaf218"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor \u03b1 antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther 49: 873-879, 2019.","DOI":"10.1111\/apt.15177"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Curtis JR, Regueiro M, Yun H, et al. Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM MarketScan<sup>\u24c7<\/sup> administrative claims database with tofacitinib trial data. Inflamm Bowel Dis 27: 1394-1408, 2021.","DOI":"10.1093\/ibd\/izaa289"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Matsuoka K, Togo K, Yoshii N, et al. Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis. Intest Res 21: 88-99, 2023.","DOI":"10.5217\/ir.2021.00154"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7882-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:11:35Z","timestamp":1791605495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7882-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7882-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7882-26"}}